Searchable abstracts of presentations at key conferences in endocrinology

ea0034s2.2 | The upside of glucocorticoids in metabolism (Supported by <emphasis role="italic">Journal of Endocrinology</emphasis>) | SFEBES2014

Maintaining the anti-inflammatory action of GC without the metabolic side effects

Cummins Carolyn , Patel Rucha , Tsai Ricky , Orellana Arturo

Synthetic glucocorticoids (GCs) including dexamethasone (Dex) are potent anti-inflammatory drugs. However, long-term use of GCs results in deleterious side effects such as hyperglycemia, hepatosteatosis, and insulin resistance. The nuclear hormone receptors LXRα and LXRβ are known for their important roles in modulating whole-body cholesterol homeostasis. Recently, we have shown that liver X receptor β (LXRβ) knockout mice are protected against Dex-induced ...

ea0077p43 | Metabolism, Obesity and Diabetes | SFEBES2021

5β-reductase is downregulated in patients with non-alcoholic fatty liver disease and hepatocellular carcinoma and controls metabolic and proliferative phenotype through LXR-dependent mechanisms

Nikolaou Nikolaos , Arvaniti Anastasia , Sanna Fabio , Saikali Michael , da Conceicao Ismael , Dempster Niall , Gathercole Laura , Cummins Carolyn , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease ranging from simple intrahepatic lipid accumulation to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). 5β-reductase (AKR1D1) is a liver enzyme that catalyses a fundamental step in bile acid (BA) synthesis. Both BAs and BA intermediates are established as potent regulators of metabolic and proliferative phenotype. We have hypothesised that AKR1D1 plays a crucial regulatory role in NAFLD and HCC. Hu...